{
    "id": 2939,
    "fullName": "TGFBR2 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "TGFBR2 over exp indicates an over expression of the Tgfbr2 receptor. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 7048,
        "geneSymbol": "TGFBR2",
        "terms": [
            "TGFBR2",
            "AAT3",
            "FAA3",
            "LDS1B",
            "LDS2",
            "LDS2B",
            "MFS2",
            "RIIC",
            "TAAD2",
            "TBR-ii",
            "TBRII",
            "TGFbeta-RII",
            "TGFR-2"
        ]
    },
    "variant": "over exp",
    "createDate": "01/15/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2206,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY2109761 inhibited the growth and migration of pancreatic cancer cells over expressing Tgfbr2 (PMID: 18413796).",
            "molecularProfile": {
                "id": 2764,
                "profileName": "TGFBR2 over exp"
            },
            "therapy": {
                "id": 2711,
                "therapyName": "LY2109761",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2766,
                    "pubMedId": 18413796,
                    "title": "LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18413796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2198,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Trabedersen (AP12009) inhibited tumor growth and vascularization, and reduced metastasis in human cell line xenograft models of pancreatic cancer over expressing Tgfbr2 (PMID: 21366804).",
            "molecularProfile": {
                "id": 2764,
                "profileName": "TGFBR2 over exp"
            },
            "therapy": {
                "id": 2705,
                "therapyName": "Trabedersen",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2756,
                    "pubMedId": 21366804,
                    "title": "Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21366804"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2764,
            "profileName": "TGFBR2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}